NCT07259915Not yet recruiting
Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck
Source: ClinicalTrials.gov · Last updated 2 Dec 2025
Brief summary (registry, in English)
The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 152 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Aug 2030
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Head and neck cancer
- NCT number
- NCT07259915
What you commit to
- Study type: Interventional
- Planned participants: 152
- From 1 Dec 2025 to the primary completion date, 1 Aug 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of radiotherapy to the head and neck region
- History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm)
- Allergy or contraindication to iodine, gadolinium, or 18F-FDG
- Patients undergoing psychiatric care that renders them incapable of giving their consent
Lab values
- Uncontrolled diabetes (fasting blood glucose greater than 12 mmol/l)
Other
- Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)
- Primary squamous cell carcinoma of the lymph nodes
- Radiochemotherapy not based on the use of cisplatin
- Pregnant or breastfeeding women
- Contraindication to MRI, CT, or PET/CT
- Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.)
- Patients under guardianship or conservatorship
- Patients deprived of their liberty by judicial or administrative decision
- Patients admitted to a health or social care facility for purposes other than research
Who the study is looking for
- Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)
- With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)
- Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg/m2 every 3 weeks or 40 mg/m2 weekly)
- Regardless of p16 status
- Affiliated with or covered by a social security system
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
| Centre Hospitalier Universitaire Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.